|Bid||1.9100 x 900|
|Ask||2.2400 x 1000|
|Day's Range||2.0101 - 2.1200|
|52 Week Range||1.7010 - 8.6500|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.25|
Akari Therapeutics, Plc (AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announced that the Company's management will present an overview of the Company and host investor meetings at the 2018 Cantor Fitzgerald Global Healthcare Conference. A live webcast of the presentation can be accessed by visiting ‘Events’ in the Investors Section on the Company's website at www.akaritx.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced results that demonstrate the potential advantages of Coversin’s unique bifunctional mode-of-action inhibiting both the complement and leukotriene pathways. “The combined inhibition of C5 and LTB4 presents a potential novel therapeutic option.
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, Aug. 20, 2018-- The Rosen Law Firm, P.A. announces that the United States District Court Southern District of New York has approved the following announcement of a proposed class action settlement ...
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria, in which patient ...
Akari Therapeutics Plc’s (NASDAQ:AKTX) latest earnings announcement in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Below, I’veRead More...
Akari Therapeutics Plc (NASDAQ:AKTX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs ofRead More...
Stock Monitor: Akari Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 16, 2018 / Active-Investors.com has just released a free research report on Tetraphase Pharma, Inc. (NASDAQ: TTPH ...
Alder BioPharmaceuticals, Inc. (ALDR) was a big mover last session, as the company saw its shares more than 15% on the day amid huge volumes.
CRISPR Therapeutics AG (CRSP) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
Audentes Therapeutics, Inc. (BOLD) was a big mover last session, as the company saw its shares nearly 15% on the day amid huge volumes.
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.